SMCI
Super Micro Computer
-- 40.210 PLTR
Palantir
-- 70.960 NVDA
NVIDIA
-- 140.260 TSLA
Tesla
-- 351.420 INTC
Intel
-- 22.470 
NEWS
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial demonstrated that 92% of evaluable patients surpassed median standard-of-care progression-free survival (PFS) of 6.9 months. Notably, multi-dose cohorts showed improved peripheral T cell recovery, with one patient remaining progression-free at 40.5 months. Biopsy results confirmed gamma-delta T cell presence in the brain tumor microenvironment. The treatment showed no serious adverse events, with most common side effects being Grade 1-2 toxicities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment